Association of dNLR Score with Outcomes in Patients with Advanced NSCLC Under Immunotherapy Alone plus /- Chemotherapy Upfront

被引：0
|
作者：
Gorria, T. [1 ]
Torres-Jimenez, J. [1 ,2 ]
Auclin, E. [3 ]
Castro, N. [4 ]
Albarran-Artahona, V. [1 ]
Ruffinelli, J. C. [5 ]
Pinato, D. [6 ]
Routy, B. [7 ]
Nana, F. Aboubakar [8 ]
Reyes, R. [1 ]
Vinolas, N. [1 ,9 ]
Teixido, C. [1 ,9 ]
Blanc-Durand, F. [10 ]
Planchard, D. [10 ]
Lopes, G. [11 ]
Nadal, E. [5 ]
Arasanz, H. [4 ,12 ]
Pascal, M. [1 ,9 ]
Prat, A. [1 ,9 ]
Reguart, N. [1 ,9 ]
Besse, B. [10 ]
Mezquita, L. [1 ,9 ]
机构：
[1] Hosp Clin Barcelona, Barcelona, Spain
[2] Hosp Univ Ramon & Cajal, Barcelona, Spain
[3] Hop European George Pompidou, Paris, France
[4] Hosp Univ Navarra, Pamplona, Spain
[5] Catalan Inst Oncol, Barcelona, Spain
[6] Hammersmith Hosp, Imperial Coll London, London, England
[7] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[8] Catholic Univ Louvain, Inst Rech Expt & Clin IREC, Pole Pneumol ORL & Dermatol PNEU, Brussels, Belgium
[9] IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumor, August Pi Sunyer Biomed Res Inst, Barcelona, Spain
[10] Gustave Roussy, Villejuif, France
[11] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[12] IdiSNA, Oncoimmunol Grp, Navarrabiomed, Pamplona, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
dNLR-score; Immunotherapy; Prognostic Factor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-09
引用
收藏
页码：S386 / S386
页数：1
相关论文
共 50 条
  • [21] Immune-related adverse events in advanced NSCLC treated with immunotherapy alone or concurrent chemotherapy and immunotherapy.
    Melson, John
    Reed, Daniel
    Horton, Bethany J.
    Moore, Margaret
    Brown, Jacqueline Theresa
    Gentzler, Ryan D.
    Hall, Richard Delmar
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [22] Tumor-Infiltrating Lymphocytes (TIL) and Outcomes with Immunotherapy (ICI) or Chemotherapy in Advanced NSCLC (aNSCLC) Patients
    Mezquita, L.
    Gataa, I.
    Rossoni, C.
    Auclin, E.
    Kossai, M.
    Aboubakar, F.
    Le Moulec, S.
    Masse, J.
    Masson, M.
    Radosevic-Robin, N.
    Rouanne, M.
    Bluthgen, M.
    Caramella, C.
    Hendriks, L.
    Gazzah, A.
    Planchard, D.
    Pignon, J.
    Besse, B.
    Adam, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S351 - S352
  • [23] Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
    Huang, Hongxiang
    Zhong, Peiyuan
    Zhu, Xie
    Fu, Silv
    Li, Siling
    Peng, Sujuan
    Liu, Yangyang
    Lu, Zhihui
    Chen, Li
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [24] Real-World Treatment Patterns and Outcomes in Patients With Advanced NSCLC Treated After Prior Chemotherapy and Immunotherapy
    Haggstrom, D.
    Mhatre, S. K.
    Chen, F.
    Gao, R.
    Carroll, C.
    Patel, R.
    Park, J.
    Descoteaux, A.
    Stokes, M.
    Daniel, D.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S409 - S409
  • [25] Intercalating and Maintenance Use of Gefitinib plus Chemotherapy versus Chemotherapy Alone in Selected Advanced NSCLC: A Phase III Study
    Jian, Hong
    Li, Wei
    Ma, Zhiyong
    Huang, Jianjin
    Feng, Jifeng
    Song, Yong
    Gao, Beili
    Zhu, Huili
    Tao, Min
    Bai, Chong
    Ma, Shenglin
    Pan, Hongming
    Qin, Shukui
    Hua, Dong
    Yu, Yongfeng
    Lu, Shun
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S236 - S236
  • [26] Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC
    Lu, S.
    Yu, Y.
    Yu, X.
    Hu, Y.
    Ma, Z.
    Li, X.
    Zhuang, W.
    Liu, Y.
    Li, W.
    Cui, J.
    Wang, D.
    Liao, W.
    Wang, M.
    Zhou, J.
    Wang, Z.
    Sun, Y.
    Gao, J.
    Bao, Y.
    Liang, L.
    Wang, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S816 - S817
  • [27] THE COMBINATION CHEMOTHERAPY OF CARBOPLATIN AND WEEKLY PACLITAXEL PLUS BEVACIZUMAB IN PATIENTS WITH ADVANCED NSCLC
    Kitaguchi, S.
    Kagawa, M.
    Yamaguchi, K.
    Watanabe, M.
    Ogawa, T.
    Furonaka, O.
    Sugahara, F.
    Egawa, H.
    ANNALS OF ONCOLOGY, 2013, 24
  • [28] Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy
    Russano, M.
    Cantini, L.
    B, A. P.
    George, R.
    Nunes, P.
    Tolba, K.
    Dutra, C.
    Chico, I.
    Cortellini, A.
    Pecci, F.
    Alessi, J. V.
    Ricciuti, B.
    Ramkissoon, S.
    Aerts, J. G.
    Agrawal, S.
    Saini, K. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S854 - S854
  • [29] Randomized Trial of Maintenance Chemotherapy Versus SBRT plus Maintenance Chemotherapy for Advanced NSCLC - Feasibility and Early Outcomes
    Wardak, Zabi
    Gerber, David E.
    Ahn, Chul
    Hughes, Randall S.
    Raja, Grace
    Khan, Saad
    Dowell, Jonathan E.
    Pelosof, Lorraine
    Pulipparacharuvil, Suprabha
    Timmerman, Robert D.
    Choy, Hak
    Iyengar, Puneeth
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S425 - S425
  • [30] Prospect of immunotherapy alone in patients with advanced NSCLC with high btmb: a review and a meta-analysis
    Feiyu Zhao
    Xiaochen Qiu
    Qinna Yang
    Shuyue Gao
    Fan Yang
    Niansong Qian
    Holistic Integrative Oncology, 2 (1):
12345